COMMUNIQUÉS West-GlobeNewswire

Newron Pharmaceuticals to Participate in H.C. Wainwright 28th Annual Global Investment Conference
03/09/2026
MILAN, Italy and MORRISTOWN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for [...]
Avalo Therapeutics to Participate in Upcoming Investor Conferences
03/09/2026
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated [...]
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
03/09/2026
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today [...]
Breckenridge Distillery and Southern Glazer’s Expand Partnership Across New York and California
03/09/2026
Strategic Distribution Expansion Accelerates Growth for Breckenridge Distillery in Two of the Largest Spirits Markets in the U.S. Expanded Partnership Also Supports Rapid Growth of Breckenridge Distillery’s Ready-to- [...]
Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference
03/09/2026
TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
03/09/2026
~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting [...]
LeonaBio to Participate in Cantor Global Healthcare Conference 2026
03/09/2026
BOTHELL, Wash., Sept. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs [...]
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
03/09/2026
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today [...]
Gyre Therapeutics to Participate in Upcoming September Investor Conferences
03/09/2026
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United [...]
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
03/09/2026
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart [...]
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
03/09/2026
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]
ANI Pharmaceuticals to Present at September Investor Conferences
03/09/2026
PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the [...]
Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026
03/09/2026
ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with [...]
Biodesix to Participate in Upcoming Investor Conferences
03/09/2026
LOUISVILLE, Colo., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in three upcoming [...]
Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials
03/09/2026
Cette acquisition apporte au réseau de développement clinique précoce de Fortrea des compétences bioanalytiques dédiées et une capacité accrue alors que Worldwide poursuit sa stratégie visant à renforcer ses activités [...]
Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026
03/09/2026
SHANGHAI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, announced today that its “AI + Chronic Care” [...]
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
03/09/2026
Tokyo, Japan and Cambridge, UK, 3 September 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals Limited (“Centessa”), a wholly-owned subsidiary of Eli Lilly [...]
Tensive to receive €20 million from EIB to commercialize bioresorbable breast implant
03/09/2026
European Investment Bank (EIB) convertible loan will help fund REGENERA™ development, CE marking, manufacturing scale-up and commercialization Follows positive 12-month pivotal trial data in July First EU regulatory [...]
Egetis Therapeutics to Participate in Upcoming Investor Conferences in September
03/09/2026
STOCKHOLM, SWEDEN, Sept. 03, 2026. (GLOBE NEWSWIRE) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that it will participate in upcoming investor conferences in [...]

Pages